-+ 0.00%
-+ 0.00%
-+ 0.00%

Zealand Pharma Launches Phase 2 Dose-finding Trial for Obesity Treatment Combo

MT Newswires·11/18/2026 01:28:17
Listen to the news
01:28 AM EST, 11/18/2026 (MT Newswires) -- Zealand Pharma (ZEAL.CO) initiated the phase 2 trial to evaluate the efficacy and safety of petrelintide when administered with enicepatide in obesity patients who have at least one weight-related comorbidity. The biotechnology company said Wednesday that the Zynergy dose-finding trial is expected to consist of 480 patients, with Roche (RO.SW) sponsoring and conducting the over-40-week study. The primary endpoint will focus on the body weight percentage change over the course of the trial, with the waist circumference and hemoglobin A1c changes being secondary endpoints.